Search
paritaprevir
Indications:
- hepatitis C infection genotype 1*
* including patients with cirrhosis
Dosage:
- once a day
- used in combination with ombitasvir & ritonavir in ombitasvir/paritaprevir/ritonavir
Adverse effects:
- reactivation of hepatitis B [2]
- may cause liver injury & liver failure independent of hepatitis B [2]
Mechanism of action:
- viral protease inhibitor
General
antiviral protease inhibitor
References
- Orciari Herman A and Sofair A
Viekira Pak Approved for Hepatitis C
Physician's First Watch, Dec 22, 2014
David G. Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
- FDA News Release. Dec 19, 2014
FDA approves Viekira Pak to treat hepatitis C
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm
- PERSPECTIVES FROM NEW ADVERSE EVENT REPORTS
Institute for Safe Medication Practices. Jan 25, 2017
http://www.ismp.org/quarterwatch/pdfs/2016Q2.pdf
Component-of
dasabuvir/ombitasvir/paritaprevir/ritonavir (Viekira XR)
ombitasvir/paritaprevir/ritonavir (Viekira, Technivie)